Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spondyloarthritis in Indigenous Populations: How Classification Shapes Epidemiology.

The Journal of rheumatology·2026
Same author

Factors Associated With the High Prevalence of Metabolic Syndrome in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Arquivos brasileiros de cardiologia·2026
Same author

Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review.

Rheumatology and therapy·2026
Same author

Prospective evaluation of recombinant Herpes zoster vaccine in SSc: immunogenicity, safety and disease outcomes.

Rheumatology (Oxford, England)·2026
Same author

Impact of sex in axial spondyloarthritis: insights from the Brazilian Registry of Spondyloarthritis.

Advances in rheumatology (London, England)·2026
Same author

Clinical Relevance of Anti-Ku Autoantibody in Idiopathic Inflammatory Myopathies.

International journal of rheumatic diseases·2026

Related Experiment Video

Updated: Jun 16, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.3K

Inflammatory myopathies overlapping with systemic sclerosis: a systematic review.

Jucier Gonçalves Júnior1, Naoki Mugii2, Pleiades Tiharu Inaoka3

  • 1Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.

Clinical Rheumatology
|February 27, 2022
PubMed
Summary

Myopathy and systemic sclerosis overlap syndrome (MyoSScOS) predominantly affects women, often involving the esophagus, joints, and lungs. Further research is needed for better characterization and targeted therapies.

Keywords:
Inflammatory myopathiesMyositisSystematic reviewSystemic sclerosis

More Related Videos

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K

Related Experiment Videos

Last Updated: Jun 16, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.3K
Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K

Area of Science:

  • Rheumatology
  • Neurology
  • Immunology

Background:

  • Myopathies and systemic sclerosis overlap syndrome (MyoSScOS) is a complex condition requiring better understanding.
  • Existing literature includes limited robust studies, necessitating a comprehensive review.

Purpose of the Study:

  • To systematically review the clinical manifestations and diagnostic examinations of MyoSScOS patients.
  • To consolidate current knowledge on MyoSScOS for improved patient care and treatment strategies.

Main Methods:

  • A systematic review adhering to the PRISMA protocol was conducted.
  • Searches were performed on PubMed, Web of Science, and Scopus from January 1976 to November 2021.
  • Thirty-five relevant articles were selected based on predefined eligibility criteria, excluding non-research publications.

Main Results:

  • MyoSScOS is more prevalent in women and commonly presents with esophageal and joint involvement, Raynaud's phenomenon, and reduced forced vital capacity.
  • The diffuse subtype of systemic sclerosis was most frequent. Cardiovascular and pulmonary complications are significant causes of mortality.
  • Specific autoantibodies (anti-centromere, anti-PM/Scl, anti-Scl70, etc.) and aggressive muscle biopsy patterns were noted. Electromyography findings resemble inflammatory myopathies.

Conclusions:

  • MyoSScOS requires further characterization through robust studies to develop effective therapeutic measures and improve patient prognosis.
  • Enhanced theoretical contributions are essential for a deeper understanding and management of this overlap syndrome.